Nvax.O
Novavax Inc operates as a biotechnology company within the Health Care sector, generating revenue primarily through vaccine development and commercialization activities.
Business. Novavax Inc operates as a biotechnology company within the Health Care sector, generating revenue primarily through vaccine development and commercialization activities.
Analyst recommendations
9 analysts · consensus HoldAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Novavax Inc operates as a biotechnology company within the Health Care sector, generating revenue primarily through vaccine development and commercialization activities.
(a) Capital structure and liquidity present a complex profile. The company reports total assets of $1.18 billion against total liabilities of $1.30 billion, resulting in negative total equity of -$128 million. Cash and equivalents stand at $241 million, providing a buffer against immediate obligations. However, operating cash flow is negative at -$245 million, indicating that core operations are consuming cash rather than generating it. The debt-to-equity ratio is reported as -0.0, reflecting the negative equity base. The current ratio is not explicitly provided, but the negative equity position suggests a fragile balance sheet structure that relies heavily on cash reserves and potential external financing.
(b) Profitability metrics show mixed signals. The company generated net income of $440 million on revenue of $1.12 billion, yielding a return on equity of 68.75%. This high ROE is mechanically driven by the small, negative equity base rather than operational efficiency. Return on assets is negative at -7.47%, indicating that the asset base is not generating positive returns relative to its size. Without cohort median data for direct comparison, the negative ROA and negative operating cash flow suggest that the company is in a growth or turnaround phase where capital investment exceeds immediate returns. The EV/EBITDA ratio is negative at -9.13, further highlighting the lack of positive EBITDA generation.
- Negative equity of -$128 million and negative operating cash flow of -$245 million indicate a fragile financial position reliant on cash reserves.
- High return on equity of 68.75% is driven by negative equity rather than operational efficiency, while return on assets is negative at -7.47%.
- Analyst sentiment is moderately positive with a mean price target of $14.11 and a mean recommendation of 2.67, suggesting upside potential from the current market price of $7.48.
- Low liquidity and dilution risks are flagged, but the negative equity and cash burn present inherent financial risks that require monitoring.
- Absence of historical data and segment/geographic breakdowns limits the ability to assess growth trends and revenue concentration risks.
Bull / Bear case
analysis pipelineIn focus — financials by report
Revenue $139.5M, −79,1% YoY; Operating income −103,0% YoY.
- ▍Revenue $139.5M, −79,1% YoY
- ▍Operating income −103,0% YoY
- ▍Net income −101,8% YoY
- ▍Free cash flow −101,5% YoY
- ▍Net margin -6.8%
Revenue $147.1M, +66,6% YoY; Operating income +110,9% YoY.
- ▍Revenue $147.1M, +66,6% YoY
- ▍Operating income +110,9% YoY
- ▍Net income +121,6% YoY
- ▍Free cash flow +129,2% YoY
- ▍Net margin 11.9%
Revenue $70.4M, −16,6% YoY; Operating income −54,3% YoY.
- ▍Revenue $70.4M, −16,6% YoY
- ▍Operating income −54,3% YoY
- ▍Net income −66,8% YoY
- ▍Free cash flow −79,9% YoY
- ▍Net margin -287.3%
Revenue $239.2M, −42,4% YoY; Operating income −37,2% YoY.
- ▍Revenue $239.2M, −42,4% YoY
- ▍Operating income −37,2% YoY
- ▍Net income −34,4% YoY
- ▍Free cash flow −33,3% YoY
- ▍Net margin 44.5%
Revenue $666.7M; Operating income $515.5M.
- ▍Revenue $666.7M
- ▍Operating income $515.5M
- ▍Net margin 77.8%
Revenue $88.3M; Operating income -$131.1M.
- ▍Revenue $88.3M
- ▍Operating income -$131.1M
- ▍Net margin -91.8%
Revenue $84.5M; Operating income -$134.0M.
- ▍Revenue $84.5M
- ▍Operating income -$134.0M
- ▍Net margin -143.5%
Revenue $415.5M; Operating income $161.0M.
- ▍Revenue $415.5M
- ▍Operating income $161.0M
- ▍Net margin 39.1%
Revenue $1.12B, +64,7% YoY; Operating income +270,4% YoY.
- ▍Revenue $1.12B, +64,7% YoY
- ▍Operating income +270,4% YoY
- ▍Net income +334,8% YoY
- ▍Free cash flow +404,3% YoY
- ▍Net margin 39.2%
Revenue $682.2M, −30,6% YoY; Operating income +56,1% YoY.
- ▍Revenue $682.2M, −30,6% YoY
- ▍Operating income +56,1% YoY
- ▍Net income +65,6% YoY
- ▍Free cash flow +72,1% YoY
- ▍Net margin -27.5%
Revenue $983.7M, −50,4% YoY; Operating income +12,1% YoY.
- ▍Revenue $983.7M, −50,4% YoY
- ▍Operating income +12,1% YoY
- ▍Net income +17,2% YoY
- ▍Free cash flow +23,7% YoY
- ▍Net margin -55.4%
Revenue $1.98B, +72,9% YoY; Operating income +61,8% YoY.
- ▍Revenue $1.98B, +72,9% YoY
- ▍Operating income +61,8% YoY
- ▍Net income +62,3% YoY
- ▍Free cash flow +60,1% YoY
- ▍Net margin -33.2%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,46 |
| Revenue | —no estimate | —no estimate | 387,3M USD |
| Operating income | —no estimate | —no estimate | -93,2M USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director · Restricted Stock Units → Common StockDisposed 18 880exercise · 2026-06-20
- Director · Restricted Stock Units → Common StockDisposed 18 880exercise · 2026-06-20
- Director · Restricted Stock Units → Common StockDisposed 18 880exercise · 2026-06-20
- Director · Restricted Stock Units → Common StockDisposed 18 880exercise · 2026-06-20
- Director · Restricted Stock Units → Common StockDisposed 18 880exercise · 2026-06-20
- Director · Restricted Stock Units → Common StockDisposed 18 880exercise · 2026-06-20
- Director · Stock Option (Right to Buy) → Common StockAcquired 21 270 @ $9,13grant · 2026-06-18
- Director · Restricted Stock Units → Common StockAcquired 14 180grant · 2026-06-18
- Director · Restricted Stock Units → Common StockAcquired 14 180grant · 2026-06-18
- Director · Stock Option (Right to Buy) → Common StockAcquired 21 270 @ $9,13grant · 2026-06-18
- Director · Stock Option (Right to Buy) → Common StockAcquired 21 270 @ $9,13grant · 2026-06-18
- Director · Restricted Stock Units → Common StockAcquired 14 180grant · 2026-06-18
- Director · Stock Option (Right to Buy) → Common StockAcquired 21 270 @ $9,13grant · 2026-06-18
- Director · Restricted Stock Units → Common StockAcquired 14 180grant · 2026-06-18
- Director · Stock Option (Right to Buy) → Common StockAcquired 21 270 @ $9,13grant · 2026-06-18
- Director · Stock Option (Right to Buy) → Common StockAcquired 21 270 @ $9,13grant · 2026-06-18
- Director · Restricted Stock Units → Common StockAcquired 14 180grant · 2026-06-18
- Director · Restricted Stock Units → Common StockAcquired 14 180grant · 2026-06-18
- Director · Stock Option (Right to Buy) → Common StockAcquired 21 270 @ $9,13grant · 2026-06-18
- Director · Restricted Stock Units → Common StockAcquired 14 180grant · 2026-06-18
- Director · Restricted Stock Units → Common StockAcquired 14 180grant · 2026-06-18
- Director · Stock Option (Right to Buy) → Common StockAcquired 21 270 @ $9,13grant · 2026-06-18
- Director · Restricted Stock Units → Common StockDisposed 9 520exercise · 2026-04-25
- EVP, R&D · Stock Option (Right to Buy) → Common StockAcquired 99 500 @ $8,46grant · 2026-04-14
- EVP, R&D · Restricted Stock Units → Common StockAcquired 66 000grant · 2026-04-14
Actions
Ask Handelsavisen
- Reference data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Cash Conversion Ratiooperating_cash_flow / net_income
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Market Capmarket_price * shares_outstanding_diluted
- NOVAVAX, INC. Market data — financials · 2026-07-31
- reconciler_enqueue (reconciler) on NVAX.O · 2026-07-31
- Novavax Inc Market data — analyst estimates · 2026-07-31
- Novavax Inc Market data — ESG · 2026-07-31
- NVAX.O HA canonical relationships · 2026-07-31
Ownership & reference
Top holders
- Investment Managers · as of 2026-03-310,01 %$36M
- Investment Managers · as of 2024-06-300,00 %$150M
- Investment Managers · as of 2026-03-310,00 %$73M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$32M
- Investment Managers · as of 2026-03-310,00 %$11M
- Investment Managers · as of 2026-03-310,00 %$12M
- Investment Managers · as of 2026-03-310,00 %$11M
- Investment Managers · as of 2025-12-310,00 %$104M
- Institutional Investor · as of 2026-03-310,00 %$6M
- Investment Managers · as of 2024-12-310,00 %$3M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Funds · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$5M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Leadership
- John C. JacobsPresident, Chief Executive Officer, Director
Insider activity
- Director · Common StockOther 18 880 · 2026-06-20
- Director · Common StockOther 18 880 · 2026-06-20
- Director · Common StockOther 18 880 · 2026-06-20
- Director · Common StockOther 18 880 · 2026-06-20
- Director · Common StockOther 18 880 · 2026-06-20
- Director · Common StockOther 18 880 · 2026-06-20
- Director · Common StockOther 9 520 · 2026-04-25
- Director · Common StockOther 7 947 · 2026-03-10
- EVP, CFO and Treasurer · Common StockOther 12 223 · 2026-03-07
- EVP, CFO and Treasurer · Common StockOther 5 904 @ $9,98$59K · 2026-03-07
- EVP, CFO and Treasurer · Common StockOther 43 167 · 2026-03-03
- EVP, CFO and Treasurer · Common StockOther 20 850 @ $9,49$198K · 2026-03-03
- Director, President and CEO · Common StockOther 150 167 · 2026-03-03
- Director, President and CEO · Common StockOther 69 288 @ $9,49$658K · 2026-03-03
- EVP, Chief Strategy Officer · Common StockOther 56 334 · 2026-03-03
- EVP, Chief Strategy Officer · Common StockOther 22 429 @ $9,49$213K · 2026-03-03
- EVP, Chief Legal Officer · Common StockOther 37 500 · 2026-03-03
- EVP, Chief Legal Officer · Common StockOther 11 378 @ $9,49$108K · 2026-03-03
- EVP, Research & Development · Common StockOther 26 667 · 2026-03-03
- EVP, Research & Development · Common StockOther 11 313 @ $9,49$107K · 2026-03-03
- Director, President and CEO · Common StockOther 83 333 · 2026-03-01
- Director, President and CEO · Common StockOther 38 450 @ $10,14$390K · 2026-03-01
- EVP, CFO and Treasurer · Common StockOther 58 666 · 2026-03-01
- EVP, CFO and Treasurer · Common StockOther 28 366 @ $10,14$288K · 2026-03-01
- EVP, Chief Strategy Officer · Common StockOther 19 600 · 2026-03-01
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Shares outstanding (annual): 162.58MUnknown
- Total liabilities (annual): USD 1.3BUnknown
- EPS (diluted) (annual): USD-PER-SHARES 3Unknown
- Operating income (annual): USD 452.8MUnknown
- Net income (annual): USD 440.3MUnknown
- Cash & equivalents (annual): USD 240.63MUnknown
- Current liabilities (annual): USD 459.95MUnknown
- Shareholders' equity (annual): USD -127.75MUnknown
- Long-term debt (annual): USD 244.21MUnknown
- Operating cash flow (annual): USD -244.63MUnknown
- Cost of revenue (annual): USD 73.04MUnknown
- Revenue (annual): USD 1.12BUnknown
- Total assets (annual): USD 1.18BUnknown
- Pre-tax income (annual): USD 442.17MUnknown
- EPS (basic) (annual): USD-PER-SHARES 3Unknown
- R&D expense (annual): USD 342.32MUnknown
- Current assets (annual): USD 978.28MUnknown
- Cash & equivalents (annual): USD 530.23MUnknown
- Current liabilities (annual): USD 1.15BUnknown
- Shares outstanding (annual): 160.42MUnknown
- Operating income (annual): USD -248.93MUnknown
- Cost of revenue (annual): USD 202.74MUnknown
- Revenue (annual): USD 682.16MUnknown
- Net income (annual): USD -187.5MUnknown